Total Payments
$18,636
2024 Payments
$719.46
Companies
92
Transactions
1,075
Medicare Patients
13,059
Medicare Billing
$8.6M
Payment Breakdown by Category
Food & Beverage$18,085 (97.0%)
Education$550.27 (3.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,085 | 1,051 | 97.0% |
| Education | $550.27 | 24 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $1,378 | 102 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,366 | 87 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,313 | 80 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,140 | 64 | $0 (2024) |
| Amgen Inc. | $1,126 | 59 | $0 (2023) |
| PFIZER INC. | $689.64 | 58 | $0 (2024) |
| Genentech USA, Inc. | $640.34 | 50 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $635.80 | 36 | $0 (2024) |
| Celgene Corporation | $635.13 | 32 | $0 (2024) |
| Astellas Pharma US Inc | $602.04 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $719.46 | 31 | Novartis Pharmaceuticals Corporation ($99.16) |
| 2023 | $3,396 | 163 | E.R. Squibb & Sons, L.L.C. ($310.08) |
| 2022 | $3,084 | 162 | Janssen Biotech, Inc. ($316.26) |
| 2021 | $2,043 | 113 | Janssen Biotech, Inc. ($270.64) |
| 2020 | $2,090 | 123 | E.R. Squibb & Sons, L.L.C. ($246.93) |
| 2019 | $2,130 | 143 | Amgen Inc. ($194.85) |
| 2018 | $2,706 | 169 | Merck Sharp & Dohme Corporation ($334.08) |
| 2017 | $2,467 | 171 | Merck Sharp & Dohme Corporation ($360.14) |
All Payment Transactions
1,075 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Oncology | ||||||
| 03/28/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: Oncology | ||||||
| 03/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: Oncology | ||||||
| 03/22/2024 | PFIZER INC. | XYNTHA (Biological), BENEFIX | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: HEMATOLOGY | ||||||
| 03/21/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 03/19/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: BioOncology | ||||||
| 03/18/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $32.74 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Oncology | ||||||
| 03/07/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Oncology | ||||||
| 03/04/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $26.71 | General |
| Category: Oncology | ||||||
| 03/01/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.27 | General |
| Category: Cardiovascular | ||||||
| 02/28/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Oncology | ||||||
| 02/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.59 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Oncology | ||||||
| 02/20/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $21.49 | General |
| Category: Oncology | ||||||
| 02/16/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $20.59 | General |
| Category: Oncology | ||||||
| 02/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.09 | General |
| 02/09/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $22.06 | General |
| 02/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: Immunology | ||||||
| 02/05/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: Cardiovascular | ||||||
| 02/03/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: Rare Disease | ||||||
| 01/30/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: Oncology | ||||||
| 01/25/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Oncology | ||||||
| 01/25/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug), IDHIFA | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 2,698 | 142,881 | $5.9M | $1.5M |
| 2022 | 37 | 2,383 | 89,302 | $4.7M | $1.6M |
| 2021 | 54 | 3,784 | 196,340 | $9.1M | $3.1M |
| 2020 | 55 | 4,194 | 192,407 | $7.9M | $2.4M |
Total Patients
13,059
Total Services
620,930
Medicare Billing
$8.6M
Procedure Codes
185
All Medicare Procedures & Services
185 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 12,003 | $1.9M | $520,454 | 27.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 57 | 13,140 | $880,380 | $239,412 | 27.2% |
| J1575 | Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin | Office | 2023 | 20 | 15,550 | $741,269 | $193,494 | 26.1% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 25 | 4,410 | $595,350 | $159,913 | 26.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 362 | 819 | $322,727 | $77,142 | 23.9% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 11 | 1,720 | $230,028 | $59,326 | 25.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 34 | 215 | $115,629 | $28,543 | 24.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 70 | 72,420 | $152,082 | $28,096 | 18.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 49 | 276 | $121,078 | $26,385 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 306 | 384 | $107,171 | $24,990 | 23.3% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 14 | 4,140 | $102,092 | $24,675 | 24.2% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 15 | 3,860 | $97,272 | $24,023 | 24.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 12 | 1,200 | $82,908 | $20,052 | 24.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 601 | 2,016 | $47,000 | $15,219 | 32.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 136 | 325 | $70,346 | $15,111 | 21.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 109 | $60,289 | $14,692 | 24.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 130 | 609 | $58,226 | $12,860 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $40,788 | $9,425 | 23.1% |
| 96369 | Infusion into tissue for therapy or prevention, 1 hour or less | Office | 2023 | 20 | 63 | $29,427 | $6,559 | 22.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 62 | 68 | $26,795 | $6,552 | 24.5% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 42 | 228 | $24,056 | $5,805 | 24.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 98 | 461 | $20,565 | $4,900 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $18,864 | $4,565 | 24.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 18 | 87 | $18,544 | $4,223 | 22.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 100 | $9,231 | $1,810 | 19.6% |
About Dr. Benjamin Downie, MD
Dr. Benjamin Downie, MD is a Medical Oncology healthcare provider based in Clovis, New Mexico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1477765550.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Downie, MD has received a total of $18,636 in payments from pharmaceutical and medical device companies, with $719.46 received in 2024. These payments were reported across 1,075 transactions from 92 companies. The most common payment nature is "Food and Beverage" ($18,085).
As a Medicare-enrolled provider, Downie has provided services to 13,059 Medicare beneficiaries, totaling 620,930 services with total Medicare billing of $8.6M. Data is available for 4 years (2020–2023), covering 185 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Clovis, NM
- Active Since 05/03/2007
- Last Updated 09/03/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1477765550
Products in Payments
- KEYTRUDA (Biological) $991.04
- OPDIVO (Biological) $700.13
- DARZALEX (Biological) $667.76
- IMBRUVICA (Drug) $377.90
- JAKAFI (Drug) $332.26
- Halaven (Drug) $331.56
- Kyprolis (Biological) $321.50
- NERLYNX (Drug) $274.38
- Imbruvica (Drug) $274.21
- XTANDI (Drug) $269.37
- GILOTRIF (Drug) $262.27
- Lenvima (Drug) $250.71
- SARCLISA (Biological) $237.38
- VERZENIO (Drug) $235.12
- REBLOZYL (Biological) $232.56
- PROMACTA (Drug) $232.14
- LIBTAYO (Biological) $216.78
- EMEND (Drug) $213.09
- BOSULIF (Drug) $205.01
- MONJUVI (Drug) $201.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.